Insulet Gross Profit 2010-2025 | PODD
Insulet annual/quarterly gross profit history and growth rate from 2010 to 2025. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Insulet gross profit for the quarter ending June 30, 2025 was $0.452B, a 36.66% increase year-over-year.
- Insulet gross profit for the twelve months ending June 30, 2025 was $1.669B, a 29.18% increase year-over-year.
- Insulet annual gross profit for 2024 was $1.446B, a 24.64% increase from 2023.
- Insulet annual gross profit for 2023 was $1.16B, a 43.98% increase from 2022.
- Insulet annual gross profit for 2022 was $0.806B, a 7.11% increase from 2021.
| Insulet Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2024 | $1,446 |
| 2023 | $1,160 |
| 2022 | $806 |
| 2021 | $752 |
| 2020 | $582 |
| 2019 | $480 |
| 2018 | $370 |
| 2017 | $277 |
| 2016 | $211 |
| 2015 | $133 |
| 2014 | $127 |
| 2013 | $112 |
| 2012 | $92 |
| 2011 | $67 |
| 2010 | $44 |
| 2009 | $18 |
| Insulet Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2025-06-30 | $452 |
| 2025-03-31 | $409 |
| 2024-12-31 | $431 |
| 2024-09-30 | $377 |
| 2024-06-30 | $331 |
| 2024-03-31 | $307 |
| 2023-12-31 | $361 |
| 2023-09-30 | $293 |
| 2023-06-30 | $265 |
| 2023-03-31 | $241 |
| 2022-12-31 | $217 |
| 2022-09-30 | $188 |
| 2022-06-30 | $190 |
| 2022-03-31 | $210 |
| 2021-12-31 | $213 |
| 2021-09-30 | $189 |
| 2021-06-30 | $183 |
| 2021-03-31 | $168 |
| 2020-12-31 | $161 |
| 2020-09-30 | $152 |
| 2020-06-30 | $143 |
| 2020-03-31 | $127 |
| 2019-12-31 | $134 |
| 2019-09-30 | $123 |
| 2019-06-30 | $116 |
| 2019-03-31 | $107 |
| 2018-12-31 | $110 |
| 2018-09-30 | $102 |
| 2018-06-30 | $82 |
| 2018-03-31 | $76 |
| 2017-12-31 | $80 |
| 2017-09-30 | $74 |
| 2017-06-30 | $65 |
| 2017-03-31 | $59 |
| 2016-12-31 | $61 |
| 2016-09-30 | $56 |
| 2016-06-30 | $50 |
| 2016-03-31 | $44 |
| 2015-12-31 | $42 |
| 2015-09-30 | $32 |
| 2015-06-30 | $31 |
| 2015-03-31 | $29 |
| 2014-12-31 | $21 |
| 2014-09-30 | $38 |
| 2014-06-30 | $36 |
| 2014-03-31 | $33 |
| 2013-12-31 | $33 |
| 2013-09-30 | $27 |
| 2013-06-30 | $27 |
| 2013-03-31 | $25 |
| 2012-12-31 | $25 |
| 2012-09-30 | $24 |
| 2012-06-30 | $22 |
| 2012-03-31 | $20 |
| 2011-12-31 | $20 |
| 2011-09-30 | $19 |
| 2011-06-30 | $15 |
| 2011-03-31 | $14 |
| 2010-12-31 | $14 |
| 2010-09-30 | $12 |
| 2010-06-30 | $10 |
| 2010-03-31 | $8 |
| 2009-12-31 | $7 |
| 2009-09-30 | $6 |
| 2009-06-30 | $3 |
| 2009-03-31 | $2 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $23.925B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $230.889B | 27.07 |
| Boston Scientific (BSX) | United States | $156.325B | 37.28 |
| Stryker (SYK) | United States | $149.639B | 30.46 |
| EssilorLuxottica (ESLOY) | France | $141.259B | 0.00 |
| Medtronic (MDT) | Ireland | $119.046B | 16.78 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.750B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.937B | 25.13 |
| ResMed (RMD) | United States | $40.192B | 28.75 |
| Agilent Technologies (A) | United States | $35.696B | 23.06 |
| GE HealthCare Technologies (GEHC) | United States | $33.662B | 15.82 |
| Terumo (TRUMY) | Japan | $26.606B | 31.53 |
| Koninklijke Philips (PHG) | Netherlands | $26.557B | 17.57 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.018B | 13.38 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.402B | 0.00 |
| Baxter (BAX) | United States | $12.681B | 9.80 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.061B | 29.61 |
| Lantheus Holdings (LNTH) | United States | $3.733B | 10.09 |
| Envista Holdings (NVST) | United States | $3.520B | 24.63 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.349B | 14.86 |
| Perrigo (PRGO) | Ireland | $3.266B | 8.16 |
| ICU Medical (ICUI) | United States | $3.151B | 21.45 |
| Haemonetics (HAE) | United States | $2.628B | 11.73 |
| Acuren (TIC) | United States | $2.261B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $2.213B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.159B | 46.29 |
| QuidelOrtho (QDEL) | United States | $1.948B | 12.26 |
| Green Thumb Industries (GTBIF) | United States | $1.840B | 79.00 |
| AtriCure (ATRC) | United States | $1.838B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.519B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.503B | 17.74 |
| AdaptHealth (AHCO) | United States | $1.284B | 18.25 |
| Neogen (NEOG) | United States | $1.249B | 19.83 |
| BioLife Solutions (BLFS) | United States | $1.200B | 2505.00 |
| InMode (INMD) | Israel | $0.944B | 8.74 |
| Kestra Medical Technologies (KMTS) | United States | $0.829B | 0.00 |
| Valneva SE (VALN) | France | $0.753B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.740B | 0.00 |
| SNDL (SNDL) | Canada | $0.704B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.618B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.615B | 0.00 |
| ZimVie (ZIMV) | United States | $0.532B | 20.52 |
| Evolus (EOLS) | United States | $0.494B | 0.00 |
| Surmodics (SRDX) | United States | $0.487B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.479B | 16.50 |
| CeriBell (CBLL) | United States | $0.434B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.432B | 0.00 |
| Owens & Minor (OMI) | United States | $0.379B | 3.36 |
| Sanuwave Health (SNWV) | United States | $0.357B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.352B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.306B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.300B | 0.00 |
| Brainsway (BWAY) | Israel | $0.294B | 59.85 |
| High Tide (HITI) | Canada | $0.292B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.287B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.286B | 21.68 |
| Omeros (OMER) | United States | $0.283B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.260B | 0.00 |
| Cerus (CERS) | United States | $0.251B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.242B | 0.00 |
| Organigram Global (OGI) | Canada | $0.232B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.219B | 0.00 |
| Exagen (XGN) | United States | $0.217B | 0.00 |
| Quanterix (QTRX) | United States | $0.211B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.199B | 16.63 |
| FitLife Brands (FTLF) | United States | $0.175B | 0.00 |
| Biote (BTMD) | United States | $0.170B | 5.64 |
| Jushi Holdings (JUSHF) | United States | $0.149B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.114B | 0.00 |
| MacroGenics (MGNX) | United States | $0.112B | 0.00 |
| Jin Medical (ZJYL) | China | $0.111B | 0.00 |
| Fonar (FONR) | United States | $0.099B | 12.78 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.090B | 0.00 |
| Apyx Medical (APYX) | United States | $0.075B | 0.00 |
| Agape ATP (ATPC) | $0.066B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.062B | 0.00 |
| MariMed (MRMD) | United States | $0.060B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.059B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.059B | 0.00 |
| ImmuCell (ICCC) | United States | $0.058B | 33.68 |
| Zynex (ZYXI) | United States | $0.050B | 0.00 |
| Veru (VERU) | United States | $0.048B | 0.00 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| Nephros (NEPH) | United States | $0.040B | 31.08 |
| United-Guardian (UG) | United States | $0.039B | 15.02 |
| Senestech (SNES) | United States | $0.024B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.017B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Cellectar Biosciences (CLRB) | United States | $0.016B | 0.00 |
| Sharps Technology (STSS) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |